Marie C Hogan

List of Publications by Year
in descending order

75 papers	4,463 citations	136950 32 h-index	106344 65 g-index
75 all docs	75 docs citations	75 times ranked	3853 citing authors

#	Article	IF	Citations
1	A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2022, 37, 1426-1428.	0.7	5
2	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. CKJ: Clinical Kidney Journal, 2022, 15, 407-416.	2.9	3
3	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	6.2	62
4	Congenital Heart Disease in Adults with Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2022, 53, 316-324.	3.1	7
5	Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrology Dialysis Transplantation, 2021, 36, 1821-1827.	0.7	5
6	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	1.9	21
7	Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 2338-2348.	2.9	9
8	Characteristics of Patients with End-Stage Kidney Disease in ADPKD. Kidney International Reports, 2021, 6, 755-767.	0.8	10
9	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
10	Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS ONE, 2021, 16, e0252479.	2.5	4
11	Establishing a nephrology genetic clinic. Kidney International, 2021, 100, 254-259.	5.2	14
12	Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials. PLoS ONE, 2021, 16, e0257606.	2.5	12
13	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clinic Proceedings, 2021, 96, 2342-2353.	3.0	20
14	Mitochondriopathy Manifesting as Inherited Tubulointerstitial Nephropathy Without Symptomatic Other Organ Involvement. Kidney International Reports, 2021, 6, 2514-2518.	0.8	5
15	COVID-19 Vaccination and Glomerulonephritis. Kidney International Reports, 2021, 6, 2969-2978.	0.8	135
16	Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county. JHEP Reports, 2020, 2, 100166.	4.9	14
17	Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity. Kidney International Reports, 2020, 5, 2021-2031.	0.8	13
18	Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1267-1278.	4.5	24

#	Article	IF	Citations
19	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
20	Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease. Surgery, 2020, 168, 25-32.	1.9	10
21	Analysis of the polycystin complex (PCC) in human urinary exosomeâ€“like vesicles (ELVs). Scientific Reports, 2020, 10, 1500.	3.3	17
22	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4
23	Crystalglobulin-Induced Nephropathy and Keratopathy. Kidney Medicine, 2019, 1, 71-74.	2.0	10
24	Pancreatic Cysts and Intraductal Papillary Mucinous Neoplasm in Autosomal Dominant Polycystic Kidney Disease. Pancreas, 2019, 48, 698-705.	1.1	6
25	Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2018, 3, 619-624.	0.8	7
26	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.8	109
27	ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. American Journal of Kidney Diseases, 2018, 71, 294-296.	1.9	5
28	Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 571-578.	6.1	101
29	SP003GENETIC TESTING IN SUSPECTED HEREDITARY PROTEINURIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2018, 33, i346-i347.	0.7	1
30	Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1153-1161.	4.5	60
31	Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease: Polycystic Liver Disease. , 2018, , 171-195.		3
32	Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney International Reports, 2017, 2, 913-923.	0.8	42
33	Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice. Kidney International Reports, 2017, 2, 695-704.	0.8	6
34	Dietary salt restriction is beneficial to the management of autosomal dominant polycysticÂkidney disease. Kidney International, 2017, 91, 493-500.	5.2	80
35	The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression. BMC Nephrology, 2017, 18, 169.	1.8	15
36	Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative. Hemodialysis International, 2017, 21, 284-293.	0.9	7

#	Article	IF	Citations
37	Negative Staining for COL4A5 Correlates With Worse Prognosis and More Severe Ultrastructural Alterations in Males With Alport Syndrome. Kidney International Reports, 2017, 2, 44-52.	0.8	16
38	Development and Validation of a Diseaseâ€Specific Questionnaire to Assess Patientâ€Reported Symptoms in Polycystic Liver Disease. Hepatology, 2016, 64, 151-160.	7.3	43
39	Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 952-960.	0.7	54
40	The relatively poor correlation between random andÂ24-hour urine protein excretion in patients withÂbiopsy-proven glomerular diseases. Kidney International, 2016, 90, 1080-1089.	5.2	51
41	Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease. Journal of the American College of Surgeons, 2016, 223, 118-126e1.	0.5	38
42	A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterology, 2016, 16, 20.	2.0	17
43	Mutations in GANAB , Encoding the Glucosidase IIÎ± Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. American Journal of Human Genetics, 2016, 98, 1193-1207.	6.2	345
44	Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis. Liver International, 2016, 36, 595-602.	3.9	6
45	Polycystic Liver Disease: The Benefits of Targeting cAMP. Clinical Gastroenterology and Hepatology, 2016, 14, 1031-1034.	4.4	15
46	Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrology, 2015, 16, 190.	1.8	14
47	Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clinic Proceedings, 2015, 90, 1030-1037.	3.0	32
48	Closeout of the HALT-PKD trials. Contemporary Clinical Trials, 2015, 44, 48-55.	1.8	1
49	Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 155-164.e6.	4.4	90
50	Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 160-172.	6.1	439
51	Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine. Kidney International, 2014, 85, 1225-1237.	5.2	92
52	Evaluating healthâ€related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver International, 2014, 34, 1578-1583.	3.9	50
53	A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2014, 29, iv142-iv153.	0.7	34
54	Health-Related Quality of Life in Patients With Autosomal DominantÂPolycystic Kidney Disease and CKD Stages 1-4: AÂCross-sectional Study. American Journal of Kidney Diseases, 2014, 63, 214-226.	1.9	93

#	Article	IF	Citations
55	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology, 2013, 58, 409-421.	7.3	96
56	Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data. Gastroenterology, 2013, 145, 357-365.e2.	1.3	76
57	Purification of Exosome-Like Vesicles from Urine. Methods in Enzymology, 2013, 524, 225-241.	1.0	41
58	Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney International, 2012, 81, 577-585.	5.2	74
59	Epstein-Barr virus-associated nephrotic syndrome. CKJ: Clinical Kidney Journal, 2012, 5, 50-52.	2.9	10
60	Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrology Dialysis Transplantation, 2012, 27, 3532-3539.	0.7	120
61	Association Between Prior Peripherally Inserted Central Catheters and Lack of Functioning Arteriovenous Fistulas: A Case-Control Study in Hemodialysis Patients. American Journal of Kidney Diseases, 2012, 60, 601-608.	1.9	62
62	Cardiac Magnetic Resonance Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2508-2515.	4.5	43
63	The HALT Polycystic Kidney Disease Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 102-109.	4.5	125
64	Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 1052-1061.	6.1	288
65	Evaluation and Management of Pain in Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, e1-e16.	1.4	72
66	Characterization of PKD Protein-Positive Exosome-Like Vesicles. Journal of the American Society of Nephrology: JASN, 2009, 20, 278-288.	6.1	300
67	Detection of High Molecular Weight Light Chain Oligomers in Urinary Exosomes of Patients with AL Amyloidosis.. Blood, 2009, 114, 4886-4886.	1.4	3
68	What the similarities of specific polycystic liver and kidney diseases can teach us about both. Nephrology News & Issues, 2008, 22, 29-31.	0.1	2
69	PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression. Human Molecular Genetics, 2003, 12, 685-698.	2.9	54
70	PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression. Human Molecular Genetics, 2003, 12, 685-98.	2.9	20
71	Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. American Journal of Hematology, 2002, 70, 55-59.	4.1	47
72	The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nature Genetics, 2002, 30, 259-269.	21.4	683

#	Article	IF	Citations
73	Two cases of non-O157:H7 Escherichia coli hemolytic uremic syndrome caused by urinary tract infection. American Journal of Kidney Diseases, 2001, 38, e22.1-e22.6.	1.9	22
74	All-trans-retinoic acid-induced myositis: A description of two patients. American Journal of Hematology, 2000, 63, 94-98.	4.1	30
75	Allâ€transâ€retinoic acidâ€induced myositis: A description of two patients. American Journal of Hematology, 2000, 63, 94-98.	4.1	2